Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Neoplasms 2Wilms Tumor 1Sarcoma 1Ovarian Neoplasms 1Lung Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Granulocyte Colony-Stimulating Factor 5Filgrastim 5Cyclophosphamide 5Melphalan 4Busulfan 4Mesna 3Ifosfamide 3Etoposide 3Carboplatin 3sargramostim 2fludarabine 2Vorinostat 2Vincristine 2Topotecan 2Thiotepa 2Temozolomide 2Stem Cell Transplantation 2Sirolimus 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Irinotecan 2Flow Cytometry 2Cisplatin 2Bone Marrow Transplantation 2trioctyl phosphine oxide 1tariquidar 1regorafenib 1racotumomab 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Wilms Tumor × tariquidar × Clear all
NCT00011414 2019-07-16

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
29 enrolled
CNSGenitourinarySarcoma

Brain Neoplasms, Neoplasms, Wilms Tumor, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡